BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 20166766)

  • 1. Current and emerging treatment strategies for cutaneous T-cell lymphoma.
    Lansigan F; Foss FM
    Drugs; 2010 Feb; 70(3):273-86. PubMed ID: 20166766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies for cutaneous T-cell lymphomas.
    Horwitz SM
    Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S187-92. PubMed ID: 19073526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of cutaneous T cell lymphoma: current status and future directions.
    Apisarnthanarax N; Talpur R; Duvic M
    Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
    Duvic M
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.
    Chung CG; Poligone B
    Curr Hematol Malig Rep; 2015 Dec; 10(4):468-76. PubMed ID: 26626770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How I treat mycosis fungoides and Sézary syndrome.
    Prince HM; Whittaker S; Hoppe RT
    Blood; 2009 Nov; 114(20):4337-53. PubMed ID: 19696197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
    Duvic M
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current treatment strategies and emerging therapies for cutaneous lymphoma.
    Yonekura K
    J Dermatol; 2022 Feb; 49(2):223-231. PubMed ID: 34958516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
    Ramelyte E; Dummer R; Guenova E
    Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
    [No Abstract]   [Full Text] [Related]  

  • 12. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
    Photiou L; van der Weyden C; McCormack C; Miles Prince H
    Curr Oncol Rep; 2018 Mar; 20(4):32. PubMed ID: 29572582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma.
    Geskin L; Malone DC
    J Dermatolog Treat; 2018 Aug; 29(5):522-530. PubMed ID: 29191068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jul; 6(7):757-60. PubMed ID: 17763605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.
    Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
    Crit Rev Oncol Hematol; 2016 Mar; 99():228-40. PubMed ID: 26811014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choices in the treatment of cutaneous T-cell lymphoma.
    Hymes KB
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):18-23. PubMed ID: 17474355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
    Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
    Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of the primary cutaneous lymphomas.
    Prince HM; McCormack C; Ryan G; O'Keefe R; Seymour JF; Baker C
    Australas J Dermatol; 2003 Nov; 44(4):227-40; quiz 241-2. PubMed ID: 14616487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
    Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
    Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
    Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.